CPPCC member and director of Suzhou University School of Medicine, Chinese Academy of Medical Sciences Institute of Medicinal Plant, said the former director of the Shi-Lin Yang, China’s bio-pharmaceutical industry will soon usher in the development of the spring, the industry should seize the opportunity to innovate in order to achieve leaps and bounds.

 

Fortunately, opportunities for clinical

 

In the Third Session of the Eleventh National People’s Congress, Premier Wen Jiabao’s government work report, great efforts to cultivate a strategic new industries. Including bio-pharmaceutical industry. “Bio-pharmaceutical industry as an emerging industry, is a foregone conclusion.” Shi-Lin Yang, said the afternoon of March 8th CPPCC National Committee Chairman Jia Qinglin, science and technology group discussion by referring to the emerging industry is our country’s future economic development, structural adjustment is indeed very important aspect of the emerging industry in 2009, developed very well, and has become structural adjustments, to maintain the national GDP growth rate of 8.7% of the important main force, in which bio-pharmaceutical industry growth rate of 21%, and machinery manufacturing, aerospace and other industries with the top. This indicates that China’s bio-pharmaceutical industry and pharmaceutical industry has entered a very important stage of development. He suggested that the relevant medical associations, societies should be carefully studied our country’s future economic restructuring, conversion and other growth opportunities, stronger, bigger and biomedicine. In addition, trade organizations, industry organizations should seize this important opportunity to national authorities strive for more and better policies to promote the bio-pharmaceutical industry development.

 

“From the biomedical innovation in terms of development potential is enormous.” Shi-Lin Yang said that the State Development and Reform Commission has issued a document devoted to the establishment of a special bio-pharmaceutical industry to carry out innovative drugs for their support. Last year, the State Food and Drug Administration approved more than 700 drugs, of which about 600 or so is an innovative drug, accounting for 80%. Long-term development planning in our country among the 16 major projects there are two belong to the area of health – one for the state of major diseases, and the second for innovative drugs. At the same time, create a platform for innovative medicines has laid a good foundation. As a major national scientific and technological special judge, Shi-Lin Yang estimates, “Eleventh Five-Year” period, the state support for some of the major pharmaceutical R & D projects in the “Shier Wu” period to the market. “After nearly 10 years, or even 20 years of accumulation, a group of good, have a foundation, there are promising innovative drugs are expected in the ‘Shier Wu’ during the launch, which will promote the development of China’s entire pharmaceutical industry.”

 

Focus on innovation

 

Opportunities are always accompanied by challenges for the biomedical industry is no exception. With the continuous advance of the new medical reform, pharmaceutical market “pie” further bigger. However, in the “sub-cake” in the process of the problems faced by the pharmaceutical industry continue to increase. “For example, drug prices, ‘two’ salary increase in four voices, the upcoming release of new version of GMP standards for improvement, we should transform have to spend money, all of which are increasing business operating costs. In fact the pharmaceutical industry’s profit margins Yue Lai The smaller, survival and development are increasingly not easy. ”

 

Shi-Lin Yang said, “The only way out is to innovate drugs must do more!” In the increasingly high cost, generic drugs can not raise the price of the innovative drugs have become very important to enhance the profitability of the entire industry in one direction. He suggested that enterprises, especially large enterprises in the new drug innovation should make more efforts to promote the healthy development of enterprises and industries.

 

Today, the National Development and Reform Commission, Ministry of Science and other related departments for the support of scientific and technological innovation is gaining momentum. Shi-Lin Yang said that with the Ministry of Science and major projects, for example, the state has invested several billion this year, is expected to “Shier Wu” period will deploy nearly billion, “Shi Sanwu” will reach 15 billion yuan. From the “Eleventh Five-Year” situation, a lot of money to support the platform for building, “but I believe that the ‘Shier Wu’, ‘Shi Sanwu’, a special focus on the major national science and technology to support a variety of research, is to promote the development of pharmaceutical industry the core. “He believes that companies must rely on innovation and be a good product, there is no good product, businesses rely on advertising may increase sales, but also increased business costs, while the profit margins did not improve. “True To increase profitability, will certainly build the new medicines, the State there are many preferential policies, including in the price, tax will support drug discovery.”

 

According to the statistics show that in 2009 industrial output value of China’s pharmaceutical industry accounted for only 2.7% of the total GDP. According to international standards, the proportion of GDP reached 5% of total output value of industry be regarded as a pillar industry. Shi-Lin Yang suggested that domestic pharmaceutical enterprises, especially bio-pharmaceutical enterprises should seize the right opportunities for new drug innovation focused support to accelerate innovation and research, promote development of the industry. “If the growth rate of China’s pharmaceutical industry from 21% to break through to 50%, GDP, increased from 2.7% to 5%, and pharmaceutical industry will be able to become a pillar industry of new and emerging industries, it is our generation or the next generation of medical people want to work toward. ”